Diagnostics and services
At the Lung and Thoracic Oncology Center, we guarantee the best possible diagnosis and treatment for all patients with tumors of the thoracic cavity according to the latest scientific findings and international guidelines. A highly qualified team of experts ensures that patients receive a treatment concept that is individually tailored to their situation: from disease detection to treatment and aftercare.
An interdisciplinary team of medical specialists and oncology experts is available to you at our center for assessment, consultation and treatment. Together, we discuss the diagnoses and therapy recommendations for our patients in our weekly tumor boards. This enables personalized medical care tailored to the individual needs of people suffering from cancer.
As part of the webinar for patients and family members, the Lung Thoracic Oncology Center provided lay insights on various topics related to lung cancer.
The individual webinars from diagnosis to treatment can now be viewed online.
University Hospital Zurich
Comprehensive Cancer Center Zurich
Lung and Thoracic Oncology Center
Rämistrasse 100
8091 Zurich
At the CCCZ Lung and Thoracic Oncology Center, numerous specialties work together in an interdisciplinary manner. In this way, we combine the knowledge of all experts to provide holistic medical care for our patients.
At the Lung Tumor Center, we conduct intensive research to develop new diagnostic and therapeutic concepts against tumors of the thoracic cavity. We are conducting numerous clinical trials to evaluate new treatment approaches. This gives cancer patients access to new therapies beyond established standards.
Our basic research focuses on non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma (PM). For both diseases, our main goal is to identify new diagnostic biomarkers that can ideally be measured in the blood. In addition, we evaluate therapeutic approaches such as new combinations of immunotherapy and chemotherapy or modern targeted therapies.
In project “EMERGE – Unraveling plEural Mesothelioma hEteRoGeneity aiming for pErsonalized treatment”, for which we were recently awarded funding by an SNF Sinergia Grant, we are exploring the molecular and genetic features of mesothelioma. In order to find new personalized treatment options for this so far incurable cancer, it is essential to investigate the molecular composition of the tumor in detail. The goal is to be able to distinguish tumor subtypes at the molecular level and to understand the different response to available therapies.